Nicolas Bihoreau

This inventor holds 24 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 8 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Laboratoire Francais Du Fractionnement Et Des Biotechnologies, Lfb Biotechnologies, National Institute of Health and Medical Research. Active years: 2009-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicolas Bihoreau. Retrieved from https://idiyas.com/inventor/nicolas-bihoreau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24 (Patent Applications = 4)

% Patents Active = 33.3

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 115(Granted Patents)

Company Filing History:

19 out of 97

Laboratoire Francais Du Fractionnement Et Des Biotechnologies

National Institute of Health and Medical Research

patents

where one patent can have more than one assignee

Years Active: 2009-2019

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

ADCC Optimization

Coagulation Proteins

GLA-Domain Proteins

Anti-D Antibodies

Cancer Treatment

Infectious Disease

Binding Profiles

Fcgamma Receptors

Purification Methods

Transgenic Factors

Enhanced Function

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10364425 - Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units (2019-07-30),

2. 10344272 - Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units (2019-07-09),

3. 10081683 - Monoclonal antibodies with enhanced ADCC function (2018-09-25),

4. 9879089 - Use of ADCC-optimized antibodies for treating low-responder patients (2018-01-30),

5. 9850477 - Method for purifying active GLA-domain coagulation proteins (2017-12-26),

6. 9718890 - Monoclonal antibodies with enhanced ADCC function (2017-08-01),

7. 9718889 - Monoclonal antibodies with enhanced ADCC function (2017-08-01),

8. 9708409 - Monoclonal antibodies with enhanced ADCC function (2017-07-18),

9. 9359610 - Method for purifying GLA-domain coagulation proteins (2016-06-07),

10. 9212365 - Method for purifying active GLA-domain coagulation proteins (2015-12-15),

11. 9109020 - Use of ADCC-optimized antibodies for treating weak patients (2015-08-18),

12. 8685725 - Monoclonal antibodies with enhanced ADCC function (2014-04-01),

13. 8501171 - Use of ADCC-optimized antibodies for treating weak patients (2013-08-06),

14. 8409572 - Monoclonal antibodies with enhanced ADCC function (2013-04-02),

15. 8357370 - Anti-D monoclonal antibodies (2013-01-22),

Title: The Innovations of Nicolas Bihoreau: A Leader in Biotechnology

Introduction: Nicolas Bihoreau, based in Orsay, France, is a prominent figure in the field of biotechnology, recognized for his significant contributions through numerous innovations and patents. With a total of 24 patents to his name, Bihoreau has made substantial advancements in the development of recombinant and transgenic Factor VII compositions, enhancing therapeutic approaches in medicine.

Latest Patents: Among his latest patents, Bihoreau's work focuses on a composition of recombinant or transgenic Factor VII. Each molecule of Factor VII in his inventions is characterized by having two N-glycosylation sites, with a specific emphasis on the glycan units involved. In one of his patents, the rate of Galα1,3Gal glycan moieties is maintained between 0 and 4%, highlighting the precise control and definition of the glycosylation process. This innovation offers a promising pathway for producing Factor VII with defined properties, essential for various medical applications.

Career Highlights: Throughout his career, Nicolas Bihoreau has been associated with prestigious organizations such as Laboratoire Français Du Fractionnement Et Des Biotechnologies and LFB Biotechnologies. His work in these institutions has significantly influenced the biopharmaceutical industry, particularly in the area of blood factor therapies.

Collaborations: Bihoreau has collaborated with notable colleagues, including Emmanuel Nony and Dominique Bourel. These partnerships have fostered a dynamic research environment, enabling the exploration of cutting-edge biotechnological solutions and advancements.

Conclusion: Nicolas Bihoreau exemplifies innovative thinking and dedication in the field of biotechnology. His extensive portfolio of patents underscores his role as a leading inventor, shaping the future of recombinant therapies. As he continues to push the boundaries of science, Bihoreau’s contributions will undoubtedly have a lasting impact on healthcare and therapeutic development.

Profile summary based on public USPTO records.